LON:DXRX Diaceutics (DXRX) Share Price, News & Analysis GBX 121.10 -0.90 (-0.74%) As of 05/2/2025 09:49 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesBuy This Stock About Diaceutics Stock (LON:DXRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Diaceutics alerts:Sign Up Key Stats Today's Range 120▼ 12450-Day Range 107.84▼ 146.5052-Week Range 95▼ 151Volume38,584 shsAverage Volume98,719 shsMarket Capitalization£102.20 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 160Consensus RatingBuy Company OverviewAt Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.Read More… Diaceutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreDXRX MarketRank™: Diaceutics scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingDiaceutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDiaceutics has received no research coverage in the past 90 days.Read more about Diaceutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Diaceutics is -35.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Diaceutics is -35.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiaceutics has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for DXRX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDiaceutics does not currently pay a dividend.Dividend GrowthDiaceutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for DXRX. News and Social Media3.4 / 5News Sentiment1.09 News SentimentDiaceutics has a news sentiment score of 1.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Diaceutics this week, compared to 0 articles on an average week.Search Interest1 people have searched for DXRX on MarketBeat in the last 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Diaceutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought £149.94 in company stock and sold GBX 0 in company stock.Percentage Held by Insiders34.30% of the stock of Diaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.38% of the stock of Diaceutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Diaceutics' insider trading history. Receive DXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Diaceutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DXRX Stock News HeadlinesInsider Buying: Diaceutics PLC (LON:DXRX) Insider Acquires 126 Shares of StockMay 1 at 1:23 AM | americanbankingnews.comDiaceutics (LON:DXRX) Shares Up 0.4% - Here's WhyApril 30 at 2:57 AM | americanbankingnews.comThe Man I Turn to In Times Like ThisA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.May 3, 2025 | Stansberry Research (Ad)Diaceutics PLC Expands Employee Share Incentive PlanApril 29, 2025 | tipranks.comDiaceutics PLC Enhances Employee Shareholding with New Share Incentive PlanApril 3, 2025 | tipranks.comDiaceutics PLC Aligns Employee Incentives with Share AwardsMarch 3, 2025 | tipranks.comDiaceutics Director Increases Stake Signaling Confidence in Company GrowthJanuary 31, 2025 | tipranks.comDiaceutics Enhances Employee Incentive Program with Share AwardsJanuary 30, 2025 | tipranks.comSee More Headlines DXRX Stock Analysis - Frequently Asked Questions How have DXRX shares performed this year? Diaceutics' stock was trading at GBX 123 on January 1st, 2025. Since then, DXRX shares have decreased by 1.5% and is now trading at GBX 121.10. View the best growth stocks for 2025 here. How do I buy shares of Diaceutics? Shares of DXRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Diaceutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Diaceutics investors own include 4D pharma (DDDD), Rolls-Royce Holdings plc (RR.L), Abcam (ABC), B&M European Value Retail (BME), BP (BP), Coats Group (COA) and genedrive (GDR). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolLON:DXRX CIKN/A Webwww.diaceutics.com PhoneN/AFaxN/AEmployees151Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 160 High Stock Price TargetGBX 160 Low Stock Price TargetGBX 160 Potential Upside/Downside+32.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (3.37) Trailing P/E RatioN/A Forward P/E Ratio119.81 P/E GrowthN/ANet Income£-2,843,065.67 Net Margins-10.90% Pretax MarginN/A Return on Equity-7.15% Return on Assets-6.06% Debt Debt-to-Equity Ratio0.39 Current Ratio4.85 Quick Ratio9.92 Sales & Book Value Annual Sales£26.08 million Price / Sales3.92 Cash FlowGBX 38.82 per share Price / Cash Flow3.12 Book ValueGBX 45.87 per share Price / Book2.64Miscellaneous Outstanding Shares84,393,829Free FloatN/AMarket Cap£102.20 million OptionableNot Optionable Beta0.58 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (LON:DXRX) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Diaceutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Diaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.